{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:24Z","timestamp":1788883704000,"version":"build-2803163510"},"reference-count":21,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Extramedullary disease (EMD) is increasingly recognized in relapsed\/refractory multiple myeloma (MM), with central nervous system involvement (CNS-MM) representing a rare but highly aggressive manifestation associated with dismal outcomes. Data on its incidence and optimal management, particularly in the era of cellular and bispecific therapies, remain limited. We conducted a retrospective analysis of patients with MM with pathology-confirmed EMD treated at our institution between January 2000 and December 2023. CNS-MM was defined by parenchymal or leptomeningeal involvement. Clinical features, cytogenetics, treatments, and outcomes were analyzed, with predictors of CNS involvement evaluated among patients with EMD. Among 304 patients with EMD, 20 (6.5%) had CNS-MM. CNS involvement occurred a median of 19.2 months after MM diagnosis, though 15% presented at diagnosis. CNS-MM was strongly associated with high-risk cytogenetics (odds ratio [OR], 3.7) and additional visceral EMD (OR, 4.6). Median overall survival (OS) from CNS-MM diagnosis was 4.2 months. Outcomes were significantly improved in patients receiving chimeric antigen receptor T-cell therapy or bispecific antibodies, with a median OS of 19.2 months vs 1.2 months in those who did not receive immune effector therapies. Intrathecal (IT) chemotherapy demonstrated limited and transient benefit. In conclusion, CNS-MM is an aggressive complication enriched in high-risk, multifocal EMD with extremely poor prognosis. Cellular and bispecific therapies show promising activity and may meaningfully improve survival, whereas IT therapy appears to have limited efficacy. Prospective studies are needed to define optimal treatment strategies for CNS-MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020668","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:22:28Z","timestamp":1782415348000},"page":"5828-5833","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-9798","authenticated-orcid":false,"given":"Alexander","family":"Xiao","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-2621","authenticated-orcid":false,"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-7311","authenticated-orcid":false,"given":"Mustaqeem","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-1447","authenticated-orcid":false,"given":"Melinda","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"4","key":"2026090811313888500_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2026090811313888500_bib2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2026090811313888500_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2026090811313888500_bib4","first-page":"308.e1","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026090811313888500_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ajh.70138","article-title":"Extramedullary disease-Achilles heel in myeloma?","volume":"101","author":"Kumar","year":"2026","journal-title":"Am J Hematol"},{"issue":"6","key":"2026090811313888500_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"2026090811313888500_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"2026090811313888500_bib8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"2026090811313888500_bib9","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajh.27425","article-title":"Central nervous system multiple myeloma: a real-world multi-institutional study of the Greek Myeloma Study Group","volume":"99","author":"Katodritou","year":"2024","journal-title":"Am J Hematol"},{"key":"2026090811313888500_bib10","doi-asserted-by":"crossref","first-page":"101343","DOI":"10.1016\/j.blre.2025.101343","article-title":"Redefining central nervous system multiple myeloma: from rare phenomenon to emerging entity","volume":"74","author":"Landry","year":"2025","journal-title":"Blood Rev"},{"issue":"2","key":"2026090811313888500_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bjh.17717","article-title":"A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival","volume":"195","author":"Yamashita","year":"2021","journal-title":"Br J Haematol"},{"issue":"15","key":"2026090811313888500_bib12","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/bloodadvances.2025016619","article-title":"Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations","volume":"9","author":"Zanwar","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026090811313888500_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-024-01208-2","article-title":"Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma","volume":"15","author":"Bingham","year":"2025","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026090811313888500_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41408-024-01190-9","article-title":"Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma","volume":"14","author":"Nakamoto-Matsubara","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026090811313888500_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/curroncol32030182","article-title":"Extramedullary multiple myeloma: challenges and opportunities","volume":"32","author":"Ho","year":"2025","journal-title":"Curr Oncol"},{"issue":"4","key":"2026090811313888500_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2026090811313888500_bib17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1111\/bjh.70108","article-title":"Bispecific antibody therapy in CNS myeloma: early evidence from a multicentre cohort","volume":"207","author":"Noveihed","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"2026090811313888500_bib18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","article-title":"BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement","volume":"9","author":"Gaballa","year":"2025","journal-title":"Blood Adv"},{"issue":"24","key":"2026090811313888500_bib19","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2025029360","article-title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","volume":"146","author":"Chari","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026090811313888500_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar","year":"2026","journal-title":"N Engl J Med"},{"issue":"2","key":"2026090811313888500_bib21","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1111\/bjh.17343","article-title":"Thiotepa intrathecal injections for myelomatous central nervous system involvement","volume":"193","author":"Claudel","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5828\/2541460\/blooda_adv-2026-020668-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5828\/2541460\/blooda_adv-2026-020668-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:31:44Z","timestamp":1788881504000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5828\/569363\/Clinical-course-risk-factors-and-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020668","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,27]]}}}